Is Buying Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH), Having Lower Short Interest a Winning Strategy?

April 16, 2018 - By Peter Erickson

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.01, from 1.32 in 2017Q3. It is negative, as 7 investors sold Theravance Biopharma, Inc. shares while 22 reduced holdings. 12 funds opened positions while 26 raised stakes. 35.06 million shares or 1.11% less from 35.46 million shares in 2017Q3 were reported.
National Bank & Trust Of America De holds 33,683 shares. Foundation Asset Mngmt L P owns 432,532 shares. Blackrock accumulated 3.74 million shares. Swiss Natl Bank holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 71,342 shares. 125,849 are owned by Tiaa Cref Invest Management Limited Liability. State Of New Jersey Common Pension Fund D stated it has 225,459 shares or 0.02% of all its holdings. Moreover, Susquehanna Gp Llp has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 30,359 shares. Bnp Paribas Arbitrage Sa invested in 0% or 8,665 shares. State Of Wisconsin Invest Board reported 31,000 shares or 0% of all its holdings. Comml Bank Of Montreal Can reported 693 shares. Old West Investment Management Limited Company holds 113,862 shares. Jacobs Levy Equity Mgmt invested in 0.01% or 15,500 shares. Balyasny Asset Ltd Com invested 0.01% in Theravance Biopharma, Inc. (NASDAQ:TBPH). 883,096 were accumulated by State Street. Wells Fargo & Mn, California-based fund reported 135,414 shares.

The stock of Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH) registered a decrease of 1.72% in short interest. TBPH’s total short interest was 5.98M shares in April as published by FINRA. Its down 1.72% from 6.09M shares, reported previously. With 152,300 shares average volume, it will take short sellers 39 days to cover their TBPH’s short positions. The short interest to Theravance Biopharma Inc – Ordinary Shares’s float is 18.41%.

The stock decreased 0.22% or $0.05 during the last trading session, reaching $22.51. About 12,946 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 26.76% since April 16, 2017 and is downtrending. It has underperformed by 38.31% the S&P500.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.23 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Among 5 analysts covering Theravance Biopharma (NASDAQ:TBPH), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Theravance Biopharma had 6 analyst reports since October 30, 2017 according to SRatingsIntel. The company was maintained on Monday, October 30 by Robert W. Baird. The rating was initiated by Piper Jaffray with “Buy” on Thursday, March 29. The rating was maintained by Leerink Swann on Thursday, February 8 with “Outperform”. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Cantor Fitzgerald on Tuesday, November 7. As per Wednesday, November 8, the company rating was maintained by Needham. The firm earned “Buy” rating on Tuesday, February 27 by Cantor Fitzgerald.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.